Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $9.00 price objective on the stock.
Kairos Pharma Stock Performance
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
See Also
- Five stocks we like better than Kairos Pharma
- 3 Fintech Stocks With Good 2021 Prospects
- Mobileye’s High Short Interest Signals Squeeze Potential
- What Are Some of the Best Large-Cap Stocks to Buy?
- Rivian: Weathering the Storm, Poised for Growth?
- Upcoming IPO Stock Lockup Period, Explained
- Avient Stock: Manufacturing Play With Double-Digit Upside
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
